BioVersys (SIX: BIOV)

Last close As at 07/02/2026

CHF25.50

1.10 (4.51%)

Market capitalisation

CHF143m

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focussed on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Latest Insights

Healthcare | SIX — initiation

BioVersys — Targeting resistant and threatening indications

Healthcare | Comment

BioVersys (SIX:BIOV) moves closer to Phase III with CTA filing

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Marc Gitzinger

    CEO & Founder

  • Hernan Levett

    CFO